跳转至内容
Merck
  • Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting.

Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting.

The American journal of cardiology (2013-12-18)
James J DiNicolantonio, Craig J Beavers, Arthur R Menezes, Carl J Lavie, James H O'Keefe, Pascal Meier, András Vorobcsuk, Dániel Aradi, András Komócsi, Saurav Chatterjee, Fabrizio D'Ascenzo, Mauro Gasparini, Jasper Brugts, Giuseppe Biondi-Zoccai
摘要

A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica (EMBASE) were searched up to March 2013 for suitable randomized controlled trials. Data were pooled using random-effects model for pairwise analyses. A total of 4 trials with 601 patients were included in this analysis. Pairwise analyses showed that compared with metoprolol, carvedilol significantly reduced the incidence of postoperative atrial fibrillation (odds ratio 0.50, 95% confidence interval 0.32 to 0.80). In conclusion, compared with metoprolol, carvedilol significantly reduces the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting.

材料
货号
品牌
产品描述

Sigma-Aldrich
卡维地洛, ≥98% (HPLC), solid
Supelco
Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material
USP
卡维地洛, United States Pharmacopeia (USP) Reference Standard
卡维地洛, European Pharmacopoeia (EP) Reference Standard
卡维地洛, European Pharmacopoeia (EP) Reference Standard